BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, April 20, 2026
Home » Authors » Mari Serebrov

Articles by Mari Serebrov

CMS in a pressure cooker over proposed Part D changes

March 4, 2014
By Mari Serebrov
With the comment deadline only a few days away, opposition to the Centers for Medicare & Medicaid Services’ (CMS) proposed changes to the Medicare Advantage and Part D prescription drug programs is boiling over.
Read More

Help needed to escalate the war on counterfeit drugs

Feb. 28, 2014
By Mari Serebrov
With the Internet and globalization making counterfeit drugs an enticing opportunity for international organized crime and a way to fund terrorism, the U.S. needs to step up the certainty and the severity of punishment for dealing in counterfeit and unapproved drugs.
Read More

CMS’ protected class Part D proposals raise bipartisan red flag

Feb. 27, 2014
By Mari Serebrov
Despite deep disagreement over some provisions in a proposed Medicare Part D rule, lawmakers on both sides of the aisle opposed the Centers for Medicare & Medicaid Services’ (CMS) proposal to remove immunosuppressants and antidepressants from protected class status.
Read More

Drugmakers take aim at Canadian patent policies

Feb. 26, 2014
By Mari Serebrov
While the biopharma industry once again wants Canada placed on the U.S. Trade Representative’s priority watch list because of its policies that erode the value of drug patents, Eli Lilly and Co. has taken the matter into its own hands.
Read More

U.S. FDA’s Margaret Hamburg: No bull’s eye on Indian drug developers

Feb. 25, 2014
By Mari Serebrov

A rash of recent inspections that led to FDA enforcement actions against a number of Indian biopharma companies doesn’t mean the U.S. agency is targeting drugmakers in that country.


Read More

FDA reconsiders exclusivity for some fixed-dose combinations

Feb. 25, 2014
By Mari Serebrov
Given the growing importance and prevalence of fixed-dose combination (FDC) drugs, the FDA is rethinking the exclusivity for those that combine a new chemical entity (NCE) with previously approved components.
Read More

Proposed Part D rule changes meet with strong opposition

Feb. 21, 2014
By Mari Serebrov
Drugmakers, patient advocacy groups, insurance companies and medical associations are lining up en masse in opposition to proposed changes to Medicare Part D that focus on the bottom line.
Read More

Drugmakers secure spot on test flight of supply chain pilot

Feb. 20, 2014
By Mari Serebrov
The FDA has cleared 13 drugmakers for the test run of its Secure Supply Chain Pilot Program. Each company along for the ride will get expedited entry for up to five approved drugs or APIs imported into the U.S. over the next two years.
Read More

Biosimilar regulation: 1984 v. 2014

Feb. 19, 2014
By Mari Serebrov
It’s 1984. The year opens with the demise of Ma Bell, as the Bell System is broken into smaller, regional telephone companies. The idea is to end Ma’s nationwide monopoly, but the result is a handful of smaller monopolies since there still is no telephone competition. The Soviet Union leads a boycott of the Summer Olympics being held in Los Angeles, presumably as payback for the U.S. boycott of the 1980 Moscow Games, which was, in turn, a response to the Soviet war in Afghanistan. Even though Time named the computer the “Machine of the Year” two years ago, personal computers...
Read More

PhRMA pushes for European Union to be added to USTR’s priority watch list

Feb. 14, 2014
By Mari Serebrov
If brand drugmakers have their way, the EU could be counted among the countries and regions that are the worst in undermining the value of U.S. companies’ intellectual property rights.
Read More
Previous 1 2 … 260 261 262 263 264 265 266 267 268 … 320 321 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 17, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • Novel caspase-2 inhibitor shows in vivo neuroprotective effects

    BioWorld Science
    Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing